A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

Researchers from The University of Osaka identify a molecule that can support specific therapeutic targeting of AML with ...

Anthony S. Stein, MD, discusses a study of total marrow and lymphoid irradiation 20 Gy and post-transplant cyclophosphamide in acute myeloid leukemia undergoing allogeneic hematopoietic cell ...

A novel regimen significantly reduced risk for moderate to severe chronic graft-versus-host disease for certain patients who underwent allogeneic hematopoietic stem cell transplantation ...

Exicure, Inc. (Nasdaq: XCUR) today shared updates on its lead asset, GPC-100 (burixafor), a small molecule CXCR4 inhibitor. Exicure, Inc. ("Exicure") is planning for a clinical trial in Acute Myeloid ...

Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in ...

In Acute Myeloid Leukemia (AML), the bone marrow makes abnormal myeloblasts ... In particular, our scientists are world experts in the complications of blood stem-cell transplantation, including ...

More information: Shunya Ikeda et al, CAR T or NK cells targeting mismatched HLA-DR molecules in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant, Nature Cancer (2025).